Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 2.5%

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) fell 2.5% during trading on Tuesday . The company traded as low as $11.37 and last traded at $11.53. 33,077 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 387,633 shares. The stock had previously closed at $11.83.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, March 4th. BMO Capital Markets increased their price target on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Truist Financial began coverage on Y-mAbs Therapeutics in a research report on Friday. They set a “buy” rating and a $21.00 price objective on the stock. Finally, HC Wainwright increased their target price on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $17.86.

Y-mAbs Therapeutics Trading Down 4.5 %

The company has a market cap of $495.84 million, a PE ratio of -24.14 and a beta of 0.66. The firm has a 50 day moving average of $13.01 and a two-hundred day moving average of $12.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, May 7th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The company had revenue of $19.93 million during the quarter, compared to analysts’ expectations of $22.06 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. On average, research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.45 EPS for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 35,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $12.03, for a total value of $421,050.00. Following the transaction, the insider now owns 197,681 shares in the company, valued at $2,378,102.43. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CFO Bo Kruse sold 31,371 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $12.07, for a total value of $378,647.97. Following the completion of the sale, the chief financial officer now directly owns 210,877 shares in the company, valued at $2,545,285.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Thomas Gad sold 35,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the transaction, the insider now owns 197,681 shares in the company, valued at approximately $2,378,102.43. The disclosure for this sale can be found here. In the last ninety days, insiders sold 99,444 shares of company stock worth $1,203,925. 21.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Campbell & CO Investment Adviser LLC purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $562,000. Trexquant Investment LP boosted its position in shares of Y-mAbs Therapeutics by 417.5% in the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after purchasing an additional 61,785 shares during the period. GSA Capital Partners LLP increased its stake in shares of Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock worth $748,000 after purchasing an additional 92,765 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Y-mAbs Therapeutics in the 4th quarter worth $34,000. Finally, Federated Hermes Inc. boosted its stake in shares of Y-mAbs Therapeutics by 4,708.0% in the fourth quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock worth $303,000 after acquiring an additional 43,549 shares during the period. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.